Name | Number of supported studies  | Average coverage | |
|---|---|---|---|
| pericyte | 20 studies | 52% ± 20% | |
| smooth muscle cell | 18 studies | 43% ± 16% | |
| fibroblast | 17 studies | 34% ± 19% | |
| goblet cell | 6 studies | 35% ± 23% | |
| astrocyte | 6 studies | 55% ± 20% | |
| endothelial cell | 6 studies | 25% ± 11% | |
| Mueller cell | 6 studies | 73% ± 27% | |
| connective tissue cell | 5 studies | 36% ± 13% | |
| retinal pigment epithelial cell | 5 studies | 59% ± 21% | |
| mesothelial cell | 4 studies | 57% ± 2% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| thymus | 89% | 1729.71 | 578 / 653 | 82% | 31.21 | 498 / 605 |
| prostate | 80% | 1434.01 | 197 / 245 | 87% | 23.02 | 436 / 502 |
| intestine | 87% | 1442.33 | 837 / 966 | 71% | 20.81 | 376 / 527 |
| kidney | 83% | 1746.43 | 74 / 89 | 73% | 110.85 | 657 / 901 |
| breast | 73% | 1203.03 | 337 / 459 | 81% | 34.01 | 901 / 1118 |
| brain | 57% | 613.53 | 1511 / 2642 | 93% | 28.28 | 653 / 705 |
| lung | 79% | 1287.26 | 458 / 578 | 69% | 17.35 | 793 / 1155 |
| ovary | 77% | 1244.82 | 139 / 180 | 68% | 31.90 | 292 / 430 |
| uterus | 92% | 2123.64 | 157 / 170 | 50% | 17.11 | 231 / 459 |
| stomach | 56% | 2890.26 | 202 / 359 | 74% | 24.19 | 212 / 286 |
| bladder | 52% | 681.00 | 11 / 21 | 58% | 11.45 | 290 / 504 |
| esophagus | 62% | 2004.87 | 893 / 1445 | 41% | 6.91 | 75 / 183 |
| pancreas | 7% | 56.95 | 23 / 328 | 93% | 40.62 | 166 / 178 |
| spleen | 100% | 5732.69 | 241 / 241 | 0% | 0 | 0 / 0 |
| blood vessel | 100% | 22668.34 | 1332 / 1335 | 0% | 0 | 0 / 0 |
| skin | 56% | 892.31 | 1008 / 1809 | 36% | 19.49 | 169 / 472 |
| adrenal gland | 10% | 110.88 | 27 / 258 | 71% | 28.67 | 163 / 230 |
| adipose | 79% | 1464.17 | 951 / 1204 | 0% | 0 | 0 / 0 |
| muscle | 62% | 1651.28 | 499 / 803 | 0% | 0 | 0 / 0 |
| lymph node | 0% | 0 | 0 / 0 | 59% | 8.20 | 17 / 29 |
| heart | 55% | 1171.64 | 475 / 861 | 0% | 0 | 0 / 0 |
| tonsil | 0% | 0 | 0 / 0 | 53% | 10.42 | 24 / 45 |
| eye | 0% | 0 | 0 / 0 | 53% | 20.73 | 42 / 80 |
| liver | 4% | 23.68 | 8 / 226 | 46% | 8.72 | 188 / 406 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| peripheral blood | 0% | 0 | 0 / 929 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
| GO_0008285 | Biological process | negative regulation of cell population proliferation |
| GO_0061053 | Biological process | somite development |
| GO_0070367 | Biological process | negative regulation of hepatocyte differentiation |
| GO_0090103 | Biological process | cochlea morphogenesis |
| GO_0090090 | Biological process | negative regulation of canonical Wnt signaling pathway |
| GO_0060070 | Biological process | canonical Wnt signaling pathway |
| GO_0030178 | Biological process | negative regulation of Wnt signaling pathway |
| GO_0060029 | Biological process | convergent extension involved in organogenesis |
| GO_0045600 | Biological process | positive regulation of fat cell differentiation |
| GO_0001501 | Biological process | skeletal system development |
| GO_0014033 | Biological process | neural crest cell differentiation |
| GO_0035567 | Biological process | non-canonical Wnt signaling pathway |
| GO_0043065 | Biological process | positive regulation of apoptotic process |
| GO_0070365 | Biological process | hepatocyte differentiation |
| GO_0061037 | Biological process | negative regulation of cartilage development |
| GO_0002064 | Biological process | epithelial cell development |
| GO_0010721 | Biological process | negative regulation of cell development |
| GO_0030308 | Biological process | negative regulation of cell growth |
| GO_0005615 | Cellular component | extracellular space |
| GO_0016020 | Cellular component | membrane |
| GO_0005737 | Cellular component | cytoplasm |
| GO_0017147 | Molecular function | Wnt-protein binding |
| GO_0005515 | Molecular function | protein binding |
| Gene name | FRZB |
| Protein name | Frizzled-related protein Secreted frizzled-related protein 3 (sFRP-3) (Frezzled) (Fritz) (Frizzled-related protein 1) (FrzB-1) Uncharacterized protein FRZB Secreted frizzled-related protein 3 (Frizzled-related protein 1) (FrzB-1) |
| Synonyms | FRP hCG_21961 FRZB1 SFRP3 FRE FIZ |
| Description | FUNCTION: Soluble frizzled-related proteins (sFRPS) function as modulators of Wnt signaling through direct interaction with Wnts. They have a role in regulating cell growth and differentiation in specific cell types. SFRP3/FRZB appears to be involved in limb skeletogenesis. Antagonist of Wnt8 signaling. Regulates chondrocyte maturation and long bone development. FUNCTION: Soluble frizzled-related proteins (sFRPS) function as modulators of Wnt signaling through direct interaction with Wnts. They have a role in regulating cell growth and differentiation in specific cell types. SFRP3/FRZB appears to be involved in limb skeletogenesis. Antagonist of Wnt8 signaling. Regulates chondrocyte maturation and long bone development. . FUNCTION: Soluble frizzled-related proteins (sFRPS) function as modulators of Wnt signaling through direct interaction with Wnts. They have a role in regulating cell growth and differentiation in specific cell types. SFRP3/FRZB appears to be involved in limb skeletogenesis. Antagonist of Wnt8 signaling. Regulates chondrocyte maturation and long bone development. . |
| Accessions | ENST00000295113.5 Q92765 Q53QT6 A0A3G1VCY7 Q53QN4 D9ZGF6 |
